WebbTorreya advised OtiTopic on this transaction, which reinforces Torreya’s strength and leadership position as an advisor to innovative drug development companies. Torreya … Webb9 aug. 2024 · Philip Morris International (NYSE: PM) has acquired OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid …
Philip Morris International Acquires Inhaled Drug Specialist …
Webb10 aug. 2024 · Philip Morris International yesterday announced the acquisition of OtiTopic, a US respiratory drug development company with a late-stage inhalable acetylsalicylic … Webb30 mars 2024 · Phillip Morris ( PM) today announced its acquisition of OtiTopic, a U.S. respiratory drug development company with a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction. The treatment is meant to assist the more than 83 million Americans at risk of myocardial infarction. taxipreis new york
Philip Morris International Acquires Inhaled Drug Specialist …
WebbPhilip Morris acquired OtiTopic The company plans to move from Asprihale clinical trials to filing for regulatory approval as early as 2024. If approved for use, the drug will help solve a significant problem and need that faces more than 83 million people with a medium to high risk of myocardial infarction - and this is only in the United States. WebbView today's Philip Morris International Inc stock price and latest PM news and analysis. Create real-time notifications to follow any changes in the live stock price. Webb9 aug. 2024 · Pharmaceutical Headquarters Regions Greater Los Angeles Area, West Coast, Western US Founded Date Jan 1, 2012 Founders Kambiz Yadidi Operating Status Active Legal Name OtiTopic, Inc. Company Type For Profit Contact Email [email protected] Phone Number 877-443-8710 the cinnamon room singapore